FGAM
ACAD icon

Financial Gravity Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Financial Gravity Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2
Closed -$98 – 22
2020
Q1 		$98 Buy
+2
New +$82 ﹤0.01% 889

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Financial Gravity Asset Management's ACAD Position: Q2 2020 in Review

Financial Gravity Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 2 shares — an estimated $98 sold.

Financial Gravity Asset Management first reported a position in ACAD in Q1 2020 and held it in 1 quarter. The position peaked at $98 in Q1 2020. 297 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • Financial Gravity Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Financial Gravity Asset Management sold 2 Acadia Pharmaceuticals shares in Q2 2020, an estimated $98.
  • Financial Gravity Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Financial Gravity Asset Management's Acadia Pharmaceuticals position peaked at $98 in Q1 2020.
  • 297 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on Financial Gravity Asset Management's 13F filing for Q2 2020, filed 13 Aug 2020.